PARP1 and lung cancer: In addition, compared with control group, PARP inhibitors showed no statistically significant difference in improving the overall survival (OS) of patients with ovarian (HR, 0.99; 95% CI, 0.78–1.25), breast (HR, 0.74; 95% CI, 0.49–1.12), or lung cancer (HR, 1.00; 95% CI, 0.76–1.31) (Table 2).